REDX — Redx Pharma Income Statement
0.000.00%
Last trade - 00:00
- £46.68m
- £46.27m
- £4.20m
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.13 | 5.68 | 10 | 18.7 | 4.2 |
Cost of Revenue | |||||
Gross Profit | 2.78 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.38 | 13.9 | 29.8 | 35 | 38 |
Operating Profit | -6.25 | -8.2 | -19.7 | -16.3 | -33.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.33 | -9.17 | -21.4 | -17.8 | -32.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.32 | -9.21 | -21.6 | -18 | -33.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.32 | -9.21 | -21.6 | -18 | -33.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.32 | -9.21 | -21.6 | -18 | -33.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.039 | -0.054 | -0.084 | -0.061 | -0.094 |